<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917046</url>
  </required_header>
  <id_info>
    <org_study_id>090309</org_study_id>
    <nct_id>NCT00917046</nct_id>
  </id_info>
  <brief_title>The SMARTEX Heart Failure Study</brief_title>
  <acronym>SMARTEX</acronym>
  <official_title>Study of Myocardial Recovery After Exercise Training in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heartcenter Leipzig GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scientific Institute of Veruno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier du Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Levanger Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol describes a randomized multicenter clinical trial designed to test the
      hypothesis that a 12-week program of high-intensity interval training (HIIT) yields larger
      beneficial effects in stable heart failure patients than current practice, defined as either
      a similar training program with the same volume of moderate continuous training (MCT) or a
      recommendation of regular exercise at moderate intensity at individual choice (RRE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation criteria are left ventricular dimensions and function measured by
      echocardiography, aerobic capacity measured as peak oxygen uptake, quality of life, and the
      level of physical activity by questionnaires. Assessments will be made before and after the
      training program and at one year follow-up. Safety of HIIT will be assessed as incidence of
      adverse effects during the training program. Clinical events will be recorded as worsening of
      heart failure requiring intensified drug therapy (diuretics), ventricular arrhythmia,
      hospitalization due to cardiovascular disease, and all-cause mortality at one year follow-up.
      The core study has been initiated and endorsed by the European Association for Cardiovascular
      Prevention and Rehabilitation, Section for Basic and Translational Research, under the
      European Society of Cardiology, and allows for sub-studies involving one or more of the
      participating centers. Preliminary calculations suggest that a total number of 200 patients
      randomized 1:1:1 to the three intervention groups is needed to detect larger beneficial
      effects with HIIT with a p-value of 0.05 and statistical power of 0.90 (primary endpoint is
      reverse remodeling, assessed by comparison between groups of change in left ventricular
      end-diastolic dimension from baseline to 12 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison between groups in change of left ventricular end diastolic diameter from baseline to 12 weeks</measure>
    <time_frame>Baseline-12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>baseline-12 weeks- 1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>baseline - 12 weeks - 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of physical activity</measure>
    <time_frame>baseline-12 weeks- 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and adverse events</measure>
    <time_frame>baseline-12 weeks - 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ejection fraction</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1 Interval training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-intensity Interval Training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Moderate Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate continuous training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Recommendation of exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recommendation of regular exercise at moderate intensity at individual choice</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>high-intensity interval training</intervention_name>
    <description>3 weekly sessions of high-intensity interval training in 12 weeks</description>
    <arm_group_label>1 Interval training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate continuous training</intervention_name>
    <description>3 weekly sessions of moderate continuous training for 12 weeks</description>
    <arm_group_label>2 Moderate Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Recommendation of regular moderate exercise</intervention_name>
    <description>Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing</description>
    <arm_group_label>3 Recommendation of exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Congestive heart failure after myocardial infarction or dilated cardiomyopathy with:

               -  LVEF &lt; 0.35,

               -  NYHA class II - III,

               -  Stable without any signs of worsening for at least 6 weeks,

               -  Minimum 3 months of optimal medical treatment,

               -  Previous revascularisation or CRT should be more than 6 months before inclusion.

        Exclusion Criteria:

          -  Significant intercurrent illness last 6 weeks,

          -  Known severe ventricular arrhythmia with functional or prognostic significance unless
             protected with ICD,

          -  Significant ischemia,

          -  Hemodynamic deterioration or exercise-induced arrhythmia at baseline testing,

          -  Other heart disease that limits exercise tolerance (valve disease with significant
             hemodynamic consequences, hypertrophic cardiomyopathy etc.,

          -  Co-morbidity that may significantly influence one-year prognosis,

          -  Functional or mental disability that may limit exercise,

          -  Patients scheduled for heart transplant at time of inclusion,

          -  A habit of regular vigorous exercise or participation in a program of exercise
             training less than 6 months before inclusion, or participation in another clinical
             trial,

          -  Patients with COPD with FEV1 below 50% of expected values are excluded,

          -  Patients taking oral corticosteroids are excluded in all cases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Øyvind Ellingsen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NTNU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig, Herzzentrum GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universitaet Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Institute of Veruno</name>
      <address>
        <city>Veruno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitaliers de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levanger Hospital</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Støylen A, Conraads V, Halle M, Linke A, Prescott E, Ellingsen Ø. Controlled study of myocardial recovery after interval training in heart failure: SMARTEX-HF--rationale and design. Eur J Prev Cardiol. 2012 Aug;19(4):813-21. doi: 10.1177/1741826711403252. Epub 2011 Mar 21.</citation>
    <PMID>21450567</PMID>
  </reference>
  <results_reference>
    <citation>Ellingsen Ø, Halle M, Conraads V, Støylen A, Dalen H, Delagardelle C, Larsen AI, Hole T, Mezzani A, Van Craenenbroeck EM, Videm V, Beckers P, Christle JW, Winzer E, Mangner N, Woitek F, Höllriegel R, Pressler A, Monk-Hansen T, Snoer M, Feiereisen P, Valborgland T, Kjekshus J, Hambrecht R, Gielen S, Karlsen T, Prescott E, Linke A; SMARTEX Heart Failure Study (Study of Myocardial Recovery After Exercise Training in Heart Failure) Group. High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. Circulation. 2017 Feb 28;135(9):839-849. doi: 10.1161/CIRCULATIONAHA.116.022924. Epub 2017 Jan 12.</citation>
    <PMID>28082387</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>All-cause heart failure patients</keyword>
  <keyword>coronary artery disease etiology</keyword>
  <keyword>dilated cardiomyopathy etiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

